ixekizumab · Taltz

Monoclonal antibody

Also known as LY2439821

Approvedregulatory verdict

Evidence outlook

Approved: Psoriasis, Psoriatic Arthritis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (5)
US
  • Non-radiographic Axial Spondyloarthritis TALTZ is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.
  • Ankylosing Spondylitis TALTZ is indicated for the treatment of adult patients with active ankylosing spondylitis.Outside this platform's coverage
Product first approved 2016FDA label
JP
  • Psoriasis (plaque psoriasis, psoriatic arthritis, pustular psoriasis, erythrodermic psoriasis) - Torutsu
Product first approved 2016yakuji.co.jp
CA
  • Plaque Psoriasis TALTZ (ixekizumab) is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Psoriatic Arthritis TALTZ is indicated for the treatment of adult patients with active psoriatic arthritis who have responded inadequately to, or are intolerant to one or more disease-modifying antirheumatic drugs (DMARD). TALTZ can be used alone or in combination with a conventional DMARD (cDMARD) (e.g., methotrexate). Ankylosing Spondylitis TALTZ is indicated for the treatment of adult patients with active...
Product first approved 2016Health Canada
EU
  • Taltz: plaque psoriasis (initial); now also psoriatic arthritis and axial spondyloarthritis; holder Eli Lilly and Company (Ireland) Limited
Product first approved 2016EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (26)
Psoriasis
NCT06588283 · Eli Lilly and Company
2024-09-30 – 2026-06-01 · Psoriasis, Obesity
What this study did
NCT03364309 · Eli Lilly and Company
2018-04-26 – 2020-06-04 · Plaque Psoriasis
What this study did
NCT02718898 · Eli Lilly and Company
2016-04 – 2018-02-21 · Genital Psoriasis, Psoriasis
What this study did
NCT02634801 · Eli Lilly and Company
2016-01-20 – 2017-11-14 · Plaque Psoriasis
What this study did
NCT02561806 · Eli Lilly and Company
2015-10 – 2017-10 · Plaque Psoriasis
What this study did
NCT01624233 · Eli Lilly and Company
2012-06 – 2017-09 · Psoriasis
What this study did
NCT02513550 · Eli Lilly and Company
2015-08 – 2017-08-03 · Plaque Psoriasis
What this study did
NCT02387801 · Eli Lilly and Company
2015-04 – 2016-08 · Psoriasis
What this study did
NCT01777191 · Eli Lilly and Company
2013-03 – 2015-05 · Plaque Psoriasis
What this study did
Psoriatic Arthritis
NCT06588296 · Eli Lilly and Company
2024-09-24 – 2026-04-23 · Psoriatic Arthritis, Obesity
What this study did
NCT04610476 · University of Erlangen-Nürnberg Medical School
2020-10-19 – 2025-10-19 · Psoriatic Arthritis, Withdrawal, Reduction
What this study did
NCT02584855 · Eli Lilly and Company
2015-09-14 – 2018-10-30 · Psoriatic Arthritis
What this study did
Other / comorbidity
NCT04285229 · Eli Lilly and Company
2020-04-10 – 2022-03-17 · Spondyloarthritis
What this study did
NCT04724629 · University of Sao Paulo
2021-01-05 – 2021-07-30 · Covid19
What this study did
NCT03129100 · Eli Lilly and Company
2017-05-09 – 2021-05-27 · Axial Spondyloarthritis
What this study did
NCT02757352 · Eli Lilly and Company
2016-08-02 – 2019-05-07 · Axial Spondyloarthritis
What this study did
NCT02696798 · Eli Lilly and Company
2016-04-12 – 2019-05-03 · Spondyloarthritis
What this study did
NCT02696785 · Eli Lilly and Company
2016-05-02 – 2018-10-17 · Spondyloarthritis
What this study did
NCT01870284 · Eli Lilly and Company
2014-07 – 2018-04 · Spondylitis, Ankylosing
What this study did
Phase 2/3 (1)
Psoriasis
NCT06374979 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-05 – 2026-06 · Guttate Psoriasis
What this study did
Phase 2 (8)
Psoriasis
NCT01107457 · Eli Lilly and Company
2010-04 – 2016-07 · Psoriasis
What this study did
Other / comorbidity
NCT04589325 · Göteborg University
2022-11-09 – 2027-12 · Type1 Diabetes Mellitus
What this study did
NCT05309616 · Yale University
2025-02-20 – 2026-05-19 · Idiopathic Subglottic Stenosis
What this study did
NCT04979910 · Icahn School of Medicine at Mount Sinai
2021-08-27 – 2024-04-12 · Major Depressive Disorder
What this study did
NCT03485976 · Oregon Health and Science University
2018-05-23 – 2020-01-13 · Pityriasis Rubra Pilaris
What this study did
NCT03099538 · Mayo Clinic
2017-08-15 – 2019-06-06 · Bullous Pemphigoid, Pemphigoid
What this study did
NCT03137160 · Ohio State University
2017-05-04 – 2018-08-16 · Pyoderma Gangrenosum
What this study did
NCT00966875 · Eli Lilly and Company
2009-08 – 2012-06 · Rheumatoid Arthritis
What this study did
Phase 1 (11)
Psoriasis
NCT03073213 · Eli Lilly and Company
2017-04-13 – 2019-05-14 · Psoriasis
What this study did
NCT02993471 · Eli Lilly and Company
2016-12-22 – 2017-11-21 · Psoriasis
What this study did
Other / comorbidity
NCT07789964 · Samsung Bioepis Co., Ltd.
2026-09-04 – 2027-06-09 · Healthy
What this study did
NCT07200986 · Celltrion
2025-09-17 – 2026-03-31 · Healthy Participants
What this study did
NCT05030415 · University of New Mexico
2021-08-12 – 2024-03-25 · Lichen Planus Scalp, Lichen Planus, Lichen Planopilaris
What this study did
NCT04259346 · Eli Lilly and Company
2020-02-05 – 2021-02-19 · Healthy
What this study did
NCT03848403 · Eli Lilly and Company
2019-01-29 – 2019-07-18 · Healthy
What this study did
NCT03848416 · Eli Lilly and Company
2019-01-29 – 2019-06-07 · Healthy
What this study did
NCT02543918 · Eli Lilly and Company
2015-09 – 2015-12 · Healthy
What this study did
NCT01236118 · Eli Lilly and Company
2010-12 – 2013-01 · Rheumatoid Arthritis
What this study did
NCT01253265 · Eli Lilly and Company
2010-05 – 2011-12 · Rheumatoid Arthritis
What this study did
Phase 4 (11)
Psoriasis
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
NCT06398106 · University Hospital, Ghent
2024-12-20 – 2028-03-01 · Psoriasis Vulgaris
What this study did
NCT04537689 · Singapore General Hospital
2020-12-10 – 2027-12-31 · Plaque Psoriasis
What this study did
NCT04340076 · Radboud University Medical Center
2020-08-20 – 2025-01-31 · Psoriasis, Psoriasis Vulgaris
What this study did
NCT04083612 · University Hospital, Ghent
2020-05-04 – 2023-12-31 · Psoriasis Vulgaris
What this study did
NCT03942042 · Eli Lilly and Company
2019-07-05 – 2020-07-22 · Generalized Pustular Psoriasis, Erythrodermic Psoriasis
What this study did
NCT03573323 · Eli Lilly and Company
2018-11-09 – 2020-01-08 · Plaque Psoriasis
What this study did
Psoriatic Arthritis
NCT05855967 · Eli Lilly and Company
2023-06-27 – 2024-09-23 · Plaque Psoriasis, Psoriatic Arthritis
What this study did
NCT05080218 · Jeffrey Curtis
2021-11-15 – 2024-05-28 · Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
What this study did
NCT03151551 · Eli Lilly and Company
2017-08-24 – 2019-09-04 · Psoriatic Arthritis
What this study did
Other / comorbidity
NCT06085079 · Massachusetts Eye Research and Surgery Institution
2022-06-01 – 2024-12-30 · Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
What this study did
Early phase / not applicable (3)
Psoriasis
NCT06811558 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-02-01 – 2027-12-31 · Over 70-year-old Patients with Psoriasis
What this study did
NCT05042635 · Shanghai Yueyang Integrated Medicine Hospital
2021-10-01 – 2024-09-30 · Plaque Psoriasis
What this study did
Psoriatic Arthritis
NCT07443956 · NHS Greater Glasgow and Clyde
2026-03-09 – 2030-05 · Psoriatic Arthritis (PsA), Obesity & Overweight
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Psoriasis
NCT06945107 · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
2025-05-27 – 2027-01-19 · Plaque Psoriasis
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Early phase / not applicable (1)
Psoriasis
NCT05503875 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2023-01-01 – 2027-12-31 · Immunoclassification, Psoriasis
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Psoriatic Arthritis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ixekizumab (Taltz): this drugApprovedMonoclonal antibodyIL-17Reliable signal
NCT02349295: ACR20 response at week 24 (SPIRIT-P2): placebo 23/118 (20%) vs ixekizumab Q4W 65/122 (53%), effect size 33.8% (95% CI 22.4-45.2), p<0.0001; vs ixekizumab Q2W 59/123 (48%), effect size 28.5% (95% CI 17.1-39.8), p<0.0001
NCT01695239: ACR20 response at week 24 (SPIRIT-P1): ixekizumab Q2W 62.1%, ixekizumab Q4W 57.9%, placebo 30.2% — significantly more responders in both ixekizumab arms than placebo.
Abatacept (Orencia)ApprovedProtein / enzyme therapeuticCD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cellsReliable signal
NCT01860976: Proportion of ACR 20 Responders at Day 169 (Day 169): Abatacept 39.4% (95% CI 32.9 to 46) vs Placebo 22.3% (95% CI 16.7 to 27.9)
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Apremilast (Otezla)ApprovedSmall moleculePDE4Reliable signal
NCT01212770: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 (Baseline and Week 16): Apremilast 20 mg 28.4% | Apremilast 30 mg 40.7% vs Placebo 18.3%
NCT01172938: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 (Baseline and Week 16): Apremilast 20 mg 30.4% | Apremilast 30 mg 38.1% vs Placebo 19%
Bimekizumab (Bimzelx)ApprovedMonoclonal antibodyIL-17A/FReliable signal
NCT03896581: ACR50 at week 16: bimekizumab 160 mg 43.4% (n=267) vs placebo 6.8% (n=133), odds ratio 11.14 (95% CI 5.40 to 22.97), p<0.001 (CT.gov posted results).
NCT03895203: ACR50 at week 16: bimekizumab 160 mg Q4W 43.9% (n=431) vs placebo 10.0% (n=281), odds ratio 7.08 (95% CI 4.58 to 10.94), p<0.001; adalimumab reference arm 45.7% (n=140, not tested) (CT.gov posted results).
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaWeak signalNo reviewed efficacy summary in this indication
Deucravacitinib (Sotyktu)ApprovedSmall moleculeTYK2Reliable signal
NCT04908189: POETYK PsA-2 (NCT04908189), primary endpoint ACR20 at week 16: deucravacitinib 54.2% vs placebo 39.4%; p=0.0002
NCT04908202: POETYK PsA-1 (NCT04908202), primary endpoint ACR20 at week 16: met, p<0.0001
Etanercept (Enbrel)ApprovedProtein / enzyme therapeuticTNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha)Reliable signal
NCT02376790: ACR20 response at week 24 (primary endpoint), SEAM-PsA: etanercept monotherapy 60.9% vs methotrexate monotherapy 50.7% (P=0.029); etanercept+methotrexate combination 65.0% vs methotrexate monotherapy 50.7% (P=0.005)
NCT00317499: ACR20 joint response at Week 12: 59% etanercept vs 15% placebo (P < 0.0001)
Golimumab (Simponi)ApprovedMonoclonal antibodyTNF-alphanot yet graded
NCT02181673: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 14 (Week 14): Golimumab 75.1% vs Placebo 21.8% phase 3 result · pivotal pending
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT04882098: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (At Week 24): Group 1: Guselkumab 100 mg q8w 68.3 percentage of participants | Group 2: Guselkumab 100 mg q4w 66.6 percentage of participants | Group 3: Placebo Followed by Guselkumab 47 percentage of participants
NCT03162796: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (Week 24): Guselkumab 100 mg q8w 52% | Guselkumab 100 mg q4w 59.4% vs Placebo 22.2%
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03675308: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24): Placebo 33.5 percentage of participants (95% CI 29.3 to 37.8) | Risankizumab 57.3 percentage of participants (95% CI 52.9 to 61.8)
Secukinumab (Cosentyx)ApprovedMonoclonal antibodyIL-17Reliable signal
NCT04632927: HAQ-DI response (>=0.35-point improvement) at Week 28: secukinumab 57.1% (32/56) vs ustekinumab 27.0% (17/63); OR 3.647 (95% CI 1.601-8.311), p=0.002.
NCT02404350: ACR20 at week 16: secukinumab 300 mg load 62.6%, 150 mg load 55.5%, 150 mg no load 59.5% vs placebo 27.4%; odds ratios 4.58 (95% CI 3.16 to 6.63), 3.38 (2.35 to 4.87) and 4.02 (2.78 to 5.79), all p<0.0001 (CT.gov posted results).
Tildrakizumab (Ilumya)ApprovedMonoclonal antibodyIL-23 p19Partial signalNo reviewed efficacy summary in this indication
Tofacitinib (Xeljanz)ApprovedSmall moleculeJAK, JAK1/JAK3not yet gradedNo reviewed efficacy summary in this indication
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03104400: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Upadacitinib 15 mg 70.6% (95% CI 66.3 to 74.9) | Upadacitinib 30 mg 78.5% (95% CI 74.6 to 82.4) vs Placebo 36.2% (95% CI 31.6 to 40.7) | Adalimumab 40 mg 65% (95% CI 60.5 to 69.5)
NCT03104374: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Upadacitinib 15 mg 56.9% (95% CI 50.2 to 63.6) | Upadacitinib 30 mg 63.8% (95% CI 57.4 to 70.1) vs Placebo 24.1% (95% CI 18.3 to 29.8)
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Icotrokinra (Icotyde)Phase 3PeptideIL-23 receptornot yet gradedNo reviewed efficacy summary in this indication
NetakimabPhase 3Monoclonal antibodyIL-17Reliable signal
NCT03598751: ACR20 response at week 24: 82% (80/97) netakimab vs 9% (9/97) placebo.
SonelokimabPhase 3Antibody-derived scaffoldIL-17A/FPartial signal
NCT06641076: Primary endpoint ACR50 at week 16 met; sonelokimab 60 mg with induction: ACR50 42.1% (sponsor topline, 2026-08-10; trial blinded to week 52).
NCT05640245: ACR50 response: 46% with sonelokimab 60mg and 47% with 120mg with induction, p<0.01 versus placebo; primary endpoint met (207 patients enrolled)
Tirzepatide (Zepbound)Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
VunakizumabPhase 3Monoclonal antibodyIL-17Partial signal
NCT05055934: ACR20 at week 12: 59.5% (vunakizumab 240 mg) and 47.4% (120 mg) vs 21.6% placebo; two-sided p = 0.0011 and p = 0.0206 respectively
ZasocitinibPhase 3Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
HS-10374Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
TQH3906Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
LPX-TI641Phase 1Small moleculeTIM receptor (Treg-expanding)not yet gradedNo reviewed efficacy summary in this indication
S-4321Phase 1Multispecific antibodyPD-1 / FcγRIIb (dual)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Taltz (ixekizumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
February 2027 (1)
Phase 2Type1 Diabetes MellitusActive not recruiting
Est. primary completion 2027-02 · NCT04589325 · CT.gov ↗
What to watch
June 2027 (1)
Phase 1HealthyRecruiting
Est. primary completion 2027-06-09 · NCT07789964 · CT.gov ↗
What to watch
December 2027 (1)
Phase 4PsoriasisRecruiting
Est. primary completion 2027-12-31 · NCT04537689 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
Early phase / not applicablePsoriatic ArthritisRecruiting
Est. primary completion 2028-02 · NCT07443956 · CT.gov ↗
What to watch
March 2028 (1)
Phase 4PsoriasisRecruiting
Est. primary completion 2028-03-01 · NCT06398106 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
Phase 4PsoriasisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07352566 · CT.gov ↗
What to watch

See the full readout calendar ↗